Celgene (CELG) Was Downgraded by Bernstein to Market Perform; Dermira Has 2.03 Sentiment

December 27, 2017 - By Danny Collins

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $1.18 billion. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 2 Sell and 11 Hold. Therefore 61% are positive. Celgene Corporation has $190 highest and $83 lowest target. $135.28’s average target is 27.32% above currents $106.25 stock price. Celgene Corporation had 117 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by BMO Capital Markets on Friday, October 27. The firm earned “Buy” rating on Friday, November 6 by UBS. On Thursday, October 5 the stock rating was downgraded by Morgan Stanley to “Underweight”. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Cantor Fitzgerald on Thursday, July 27. The firm has “Outperform” rating given on Friday, June 16 by Leerink Swann. The firm has “Outperform” rating given on Friday, November 17 by BMO Capital Markets. Canaccord Genuity maintained the shares of CELG in report on Friday, November 6 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $140 target in Friday, October 27 report. The rating was maintained by Leerink Swann with “Buy” on Friday, October 20. As per Thursday, February 25, the company rating was initiated by Citigroup.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.17, from 1.34 in 2017Q2. It fall, as 44 investors sold Celgene Corporation shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Brinker Cap accumulated 0.26% or 43,623 shares. Granite Invest Prns Limited Liability Corp has 5,421 shares for 0.05% of their portfolio. Fcg Advsr Limited reported 208,469 shares. New Mexico Educational Retirement Board stated it has 72,630 shares or 0.5% of all its holdings. Preferred Limited Liability Company holds 0.04% or 436 shares in its portfolio. Ibm Retirement Fund, a New York-based fund reported 19,295 shares. 10,000 were accumulated by Cubist Systematic Strategies Limited Liability Co. Capital Wealth Planning Limited Liability Corporation invested in 0.23% or 2,000 shares. Moreover, Markston Interest Ltd Company has 1.12% invested in Celgene Corporation (NASDAQ:CELG). Burns J W And Ny invested in 44,473 shares. Horseman Capital Mngmt holds 0.19% or 6,000 shares in its portfolio. Trust Investment Advsrs, a Indiana-based fund reported 4,775 shares. Stock Yards National Bank And Tru Comm stated it has 118,679 shares or 2.03% of all its holdings. Oakworth Inc has invested 0.04% in Celgene Corporation (NASDAQ:CELG). Martin Currie has invested 0.99% of its portfolio in Celgene Corporation (NASDAQ:CELG).

The stock decreased 0.67% or $0.72 during the last trading session, reaching $106.25. About 417,281 shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since December 27, 2016 and is uptrending. It has outperformed by 0.30% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 25. They expect $1.75 earnings per share, up 24.11% or $0.34 from last year’s $1.41 per share. CELG’s profit will be $1.38B for 15.18 P/E if the $1.75 EPS becomes a reality. After $1.78 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69% negative EPS growth.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $83.65 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 24.9 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Since August 2, 2017, it had 0 insider purchases, and 5 sales for $6.27 million activity. The insider CASEY MICHAEL D sold 9,250 shares worth $1.29M. Another trade for 18,506 shares valued at $2.42 million was sold by MARIO ERNEST. 1,727 shares valued at $248,498 were sold by Curran Terrie on Monday, September 25. KAPLAN GILLA had sold 7,500 shares worth $1.01M on Wednesday, August 2.

Since January 1, 0001, it had 0 insider buys, and 9 sales for $902,226 activity.

Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on February, 27. They expect $-1.31 EPS, down 523.81% or $1.10 from last year’s $-0.21 per share. After $-1.21 actual EPS reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts 8.26% negative EPS growth.

Nea Management Company Llc holds 3.32% of its portfolio in Dermira, Inc. for 3.51 million shares. Venbio Select Advisor Llc owns 1.52 million shares or 3.18% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 1.88% invested in the company for 125,000 shares. The United Kingdom-based Abingworth Llp has invested 1.31% in the stock. Dafna Capital Management Llc, a California-based fund reported 75,500 shares.

The stock increased 0.32% or $0.09 during the last trading session, reaching $28.3. About 10,886 shares traded. Dermira, Inc. (DERM) has declined 7.44% since December 27, 2016 and is downtrending. It has underperformed by 24.14% the S&P500.